– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance – – 2026 ...
PTC Therapeutics is a commercial stage biotechnology firm. Its last Phase 2 trial, investigating PTC518 in Huntington's disease, released mixed results about the drug efficacy. We think a Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results